These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 15892169)
1. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Cicero TJ; Inciardi JA; Adams EH; Geller A; Senay EC; Woody GE; Muñoz A Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):851-9. PubMed ID: 15892169 [TBL] [Abstract][Full Text] [Related]
2. The Diversion of Ultram, Ultracet, and generic tramadol HCL. Inciardi JA; Cicero TJ; Munoz A; Adams EH; Geller A; Senay EC; Woody GE J Addict Dis; 2006; 25(2):53-8. PubMed ID: 16785220 [TBL] [Abstract][Full Text] [Related]
3. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687 [TBL] [Abstract][Full Text] [Related]
4. Assessment of the abuse of tapentadol immediate release: the first 24 months. Dart RC; Cicero TJ; Surratt HL; Rosenblum A; Bartelson BB; Adams EH J Opioid Manag; 2012; 8(6):395-402. PubMed ID: 23264317 [TBL] [Abstract][Full Text] [Related]
5. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. Cicero TJ; Inciardi JA; Muñoz A J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959 [TBL] [Abstract][Full Text] [Related]
6. Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States. Cicero TJ; Inciardi JA; Surratt H Drug Alcohol Depend; 2007 Dec; 91(2-3):115-20. PubMed ID: 17590285 [TBL] [Abstract][Full Text] [Related]
7. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone. Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252 [TBL] [Abstract][Full Text] [Related]
8. Detecting signals of opioid analgesic abuse: application of a spatial mixed effect poisson regression model using data from a network of poison control centers. Smith MY; Irish W; Wang J; Haddox JD; Dart RC Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1050-9. PubMed ID: 18803336 [TBL] [Abstract][Full Text] [Related]
9. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Cicero TJ; Adams EH; Geller A; Inciardi JA; Muñoz A; Schnoll SH; Senay EC; Woody GE Drug Alcohol Depend; 1999 Nov; 57(1):7-22. PubMed ID: 10617309 [TBL] [Abstract][Full Text] [Related]
10. Monitoring risk: post marketing surveillance and signal detection. Dart RC Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743 [TBL] [Abstract][Full Text] [Related]
11. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. Adams EH; Breiner S; Cicero TJ; Geller A; Inciardi JA; Schnoll SH; Senay EC; Woody GE J Pain Symptom Manage; 2006 May; 31(5):465-76. PubMed ID: 16716877 [TBL] [Abstract][Full Text] [Related]
12. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Cicero TJ; Surratt H; Inciardi JA; Munoz A Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):827-40. PubMed ID: 17636553 [TBL] [Abstract][Full Text] [Related]
13. FDA approvals of generic drugs: impact on the diversion of opioid analgesics with a potential for abuse. Inciardi JA; Surratt HL; Stivers Y; Cicero TJ J Opioid Manag; 2009; 5(2):81-7. PubMed ID: 19507804 [TBL] [Abstract][Full Text] [Related]
15. Trends in opioid analgesic abuse and mortality in the United States. Dart RC; Surratt HL; Cicero TJ; Parrino MW; Severtson SG; Bucher-Bartelson B; Green JL N Engl J Med; 2015 Jan; 372(3):241-8. PubMed ID: 25587948 [TBL] [Abstract][Full Text] [Related]
16. Source of drugs for prescription opioid analgesic abusers: a role for the Internet? Cicero TJ; Shores CN; Paradis AG; Ellis MS Pain Med; 2008 Sep; 9(6):718-23. PubMed ID: 18816331 [TBL] [Abstract][Full Text] [Related]
17. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173 [TBL] [Abstract][Full Text] [Related]
18. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Compton WM; Volkow ND Drug Alcohol Depend; 2006 Feb; 81(2):103-7. PubMed ID: 16023304 [TBL] [Abstract][Full Text] [Related]
19. An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride). Woody GE; Senay EC; Geller A; Adams EH; Inciardi JA; Schnoll S; Muñoz A; Cicero TJ Drug Alcohol Depend; 2003 Nov; 72(2):163-8. PubMed ID: 14636971 [TBL] [Abstract][Full Text] [Related]
20. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007. Schneider MF; Bailey JE; Cicero TJ; Dart RC; Inciardi JA; Parrino M; Muñoz A Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):778-90. PubMed ID: 19536784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]